MedTrace Logo

Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart Failure

NCT05913271 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 352

Last updated 2023-06-22

No results posted yet for this study

Summary

1. To evaluate the efficacy and safety of levosimendan in the treatment of heart failure ;
2. Guide patients to apply levosimendan individually and establish a dose adjustment program.

Conditions

Sponsors & Collaborators

  • Qianfoshan Hospital

    collaborator OTHER

  • Yi Han

    lead OTHER

Principal Investigators

  • Yi Han, doctorate · First Affiliated Hospital of Shandong First Medical University ( Qianfoshan Hospital of Shandong Province )

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-30
Primary Completion
2025-05-30
Completion
2025-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05913271 on ClinicalTrials.gov